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Purpose: Robotic-assisted laparoscopic prostatectomy (RALP) offers reportedly comparable oncologic outcomes for localized disease 
compared with open radical retropubic prostatectomy (ORRP). However, the oncologic efficacy of RALP in locally-advanced prostate 
cancer (PCa) is less clear. We report and compare our experience with RALP and ORRP in men with locally advanced PCa. 
Methods: Patients with locally advanced PCa (stage T3 or greater) were identified in both robotic and open cohorts. Clinicopathologic 
features including age, clinical stage, prostate-specific antigen, surgical margins, and Gleason score were reviewed. We further examined 
the incidence of positive surgical margins, the effect of the surgical learning curve on margins, and the need for adjuvant therapy. 
Results: From 1997 to 2010, 1,011 patients underwent RALP and 415 patients were identified who underwent  radical  retropubic 
prostatectomy (RRP) across four institutions. 140 patients in the RALP group and 95 in the RRP group had locally advanced PCa on final 
pathology. The overall robotic positive margin rate 47.1% compared with 51.4% in the RRP group. A trend towards a lower positive 
margin rate was seen after 300 cases in the RALP group, with 66.7% positive margin rate in the first 300 cases compared with 41.8% in 
the latter 700 cases. In addition, a lower incidence of biochemical recurrence was also noted in the latter cases (30.6% vs. 9.5%). 
Conclusions: Up to 2 out of 3 men undergoing RALP for locally-advanced PCa had positive margins during our initial experience. 
However, with increasing surgeon experience the overall positive margin rate decreased significantly and was comparable to the 
positive margin rate for patients with locally advanced disease undergoing ORRP over four academic institutions. We also noted a 
lower incidence of biochemical recurrence with increasing RALP experience, suggesting better oncologic outcomes with higher 
volume. Given this data, RALP has comparable oncologic outcomes compared to ORRP, especially with higher volume surgeons.
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INTRODUCTION
Prostate cancer (PCa) is the most commonly diagnosed solid 
malignancy in men and the second leading cause of male 
cancer related death in the United States [1]. The majority 
PCa is now diagnosed as clinically localized disease due to 
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Table 1. Preoperative and postoperative clinicopathologic data
Variable
RRP  
(n=95)
RALP  
(n=140)
P-value
Preoperative patient data
Mean follow-up (yr) 9.4 4.5
Mean age (yr) 60.3 62.1 0.185
Preoperative Gleason score 6.7 6.6 0.642
<6 52.6 (50) 50 (70) 0.845
7 26.3 (25) 25.0 (35) 0.765
>8 21.1 (20) 25.0 (35) 0.345
Mean preoperative PSA 9.1 8.3 0.502
<10 81.1 (77) 80.0 (112) 0.876
10–20 11.6 (11) 14.3 (20) 0.324
>20 7.3 (7) 5.7 (8) 0.234
Clinical stage
T1 55.8 (53) 53.6 (75) 0.756
T2 44.2 (42) 46.4 (65) 0.245
>T3 0 (0) 0 (0)
Postoperative pathologic data
Final Gleason score
Mean 7.2 7.2 0.893
<6 22.1 (21) 17.1 (24) 0.564
7 46.3 (44) 55.7 (78) 0.345
>8 31.6 (30) 27.2 (38) 0.456
Pathologic stage
T3a 49.5 (47) 47.1 (66) 0.456
T3b 42.1 (40) 45.7 (64) 0.754
T4 8.4 (8) 7.2 (10) 0.652
Positive margin 58.9 (56) 47.1 (66) 0.083
Biochemical recurrence 18.9 (18) 18.5 (26) 0.943
Median biochemical recur-
rence free survival (mo)
12.0 12.0 0.740
Values are presented as number (%).
RRP, radical retropubic prostatectomy; RALP, robotic-assisted laparo-
scopic prostatectomy; PSA, prostate specific antigen.
ues were obtained during regular clinic or telephone follow-
up intervals based on surgeon preference. Biochemical recur-
rence was defined as two consecutive detectable PSA levels 
≥0.2 ng/mL. 
3. Statistical analysis
The student’s t-test and multivariate analysis of variation test 
were used for comparison of preoperative and postoperative 
variables with P<0.05 were considered statistically significant. 
Logistic regression and Kaplan-Meier curve analysis was per-
formed for biochemical recurrence free survival. Statistical 
analyses were performed using the SPSS ver. 12 (SPSS Inc., 
Chicago, IL, USA). 
RESULTS
Table 1 illustrates the baseline preoperative characteristics 
widespread prostate-specific antigen (PSA) screening and 
resulting stage migration, and commonly accepted treatment 
options for localized disease include active surveillance, radi-
cal prostatectomy (RP), and radiotherapy. In cases of locally 
advanced disease, the role of RP as primary treatment remains 
uncertain, although a recent series of men with clinical T3 
PCa revealed comparable cancer specific survival rates vs. 
radiation or hormonal treatment [2].
 Over the last decade, minimally invasive surgical approach-
es to PCa have surged in popularity, with an estimated 80% 
of RPs performed with robotic assistance [3,4]. While several 
studies have shown comparable oncologic outcomes of ro-
botic-assisted laparoscopic prostatectomy (RALP) and open 
radical retropubic prostatectomy (RRP) for localized PCa, the 
oncologic efficacy of RALP vs. RRP for locally advanced PCa 
is less clear [5-7]. We report on our experience with RALP for 
pT3 PCa and assess oncologic outcomes. Additionally, we 
assess the effect of surgeon learning curve on oncologic out-
comes and compare our results to men undergoing RRP for 
pathologic stage (pT3).
MATERIALS AND METHODS
1. Study cohort
Between January 1997 and November 2008, 1,011 men un-
derwent RALP and 415 men underwent RRP across three 
institutions and patient information was collected to limit 
selection bias. Our RALP cohort was populated with patients 
from Yale University Hospital and Washington Hospital Center 
where 99% of prostatectomies were performed with the ro-
botic approach. Our RRP cohort was populated with patients 
from Georgetown University Hospital where no surgical robot 
was available during the study period. Initial evaluation for 
all men included PSA level, digital rectal exam, and a biopsy-
determined Gleason score. Two hundred and thirty-five men 
(140 RALP vs. 95 RRP) had ≥pT3 PCa on final pathology and 
were included for analysis. All RALP data was obtained from 
our Institutional Review Board-approved prospectively col-
lected database while RRP data was obtained from retrospec-
tive data collection.
2. Variables
Preoperative demographic and pathologic data including 
age, clinical stage, surgical margin status, and biopsy Gleason 
score were recorded. All RALP clinical staging was confirmed 
with intraoperative examination under anesthesia prior to 
surgery. Postoperative pathologic data including margin sta-
tus, and PSA data were also recorded. Postoperative PSA val-
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 Table 2 compares oncologic outcomes of our initial 300 
RALP vs. the latter 700. A trend towards a lower positive margin 
rate was seen after 300 cases in the RALP cohort with 66.7% 
(24/36) positive margin rate in the first 300 cases compared 
with 39.4% (41/104) in the latter 700. Additionally, there was a 
lower incidence of biochemical recurrence in the latter cases 
(30.6 [11/36] vs. 9.3% [13/104]). Kaplan-Meier analysis was 
performed between these two cohorts and showed a signifi-
cant biochemical recurrence-free survival advantage of our 
latter cases at 24 months of follow-up (Fig. 2). Median length 
of biochemical recurrence-free survival was three months in 
our initial cohort with an increase to 24 months with more 
experience (P=0.009; 95% CI, 0.19 to 1.13; HR, 0.46).
Table 2. Learning curve effect on RALP oncologic outcome for 
pT3 prostate cancer
First 300 
RALP (n=36)
Latter 700 
RALP (n=104)
P-value
Mean follow-up (yr) 6.1 3.5
Mean age (yr) 59.2 60.3 0.507
Mean preoperative PSA (ng/dL) 7.3 8.26 0.469
Preoperative PSA
<10 75.0 (27) 81.7 (85) 0.543
10–20 16.7 (6) 13.5 (14) 0.734
>20 8.3 (3) 4.8 (5) 0.385
Clinical stage
T1 44.4 (16) 56.7 (59) 0.425
T2 55.6 (20) 43.3 (45) 0.244
>T3 0 (0) 0 (0)
Mean preoperative Gleason 6.8 7.1 0.135
Preoperative Gleason
<6 55.6 (20) 48.1 (50) 0.367
7 11.1 (4) 29.8 (31) 0.654
>8 33.3 (12) 22.1 (23) 0.478
Final Gleason
Mean 7.1 7.5 0.597
<6 33.3 (12) 11.5 (12)
7 36.1 (13) 62.5 (65)
>8 30.6 (11) 26.0 (27)
Positive margin 66.7 (24) 39.4 (41) 0.004
Pathologic stage
T3a 52.8 (19) 45.2 (47) 0.105
T3b 44.4 (16) 46.2 (48) 0.156
T4 2.8 (1) 8.6 (9) 0.236
Biochemical recurrence 30.6 (11) 12.5 (13) 0.002
Median biochemical recur-
rence free survival (mo)
3.0 24.0 0.009
Values are presented as percentage (number).
RRP, radical retropubic prostatectomy; RALP, robotic-assisted laparo-
scopic prostatectomy; PSA, prostate specific antigen.
as well as postoperative pathologic and oncologic outcomes 
both RALP and RRP cohorts. There were no differences in 
age or preoperative PSA data. While 46.4% (65/140) of men 
undergoing RALP had clinically palpable disease, this data 
was not available for the RRP cohort. There were no signifi-
cant differences in postoperative Gleason score. The overall 
positive margin rate in men with advance disease undergoing 
RALP was 47.1% (66/140) compared with 58.9% (56/95) in 
the RRP group (P=0.08). At a follow-up of 3 years, 18.9% pa-
tients (18/95) in the RRP group had biochemical recurrence 
compared to 18.5% of patients (26/140) in the RALP group. 
Kaplan-Meier analysis was performed and showed a similar 
biochemical recurrence-free survival advantage between our 
RRP and RALP patients (Fig. 1). Median length of biochemical 
recurrence-free survival was twelve months for both groups 
(P=0.742; 95% confidence interval [CI], 0.51 to 1.69; hazard 
ratio [HR], 0.93).
Fig. 1. Biochemical recurrence (BCR) free survival in open vs. ro-
botic-assisted laparoscopic prostatectomy T3 patients. 
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Fig. 2. Biochemical recurrence free survival between initial 
(group 1) and latter (group 2) robotic experience.
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DISCUSSION
Historically, surgery has not been the preferred approach in 
the treatment locally advanced PCa due to the risk of subclin-
ical metastatic disease and elevated rates of positive surgical 
margins. Additionally, no randomized data comparing sur-
gery to other treatment modalities are yet available, making 
it difficult to justify the morbidity of surgery [8]. However, in 
recent years, several series have reported oncologic outcomes 
with primary surgical treatment that are similar to reported 
series of patients treated with radiotherapy in the setting of 
locally advanced disease. 
 Ward et al. [9] first reported their series of 842 patients with 
locally advanced disease treated with RRP in 2005 with a 
5-year disease specific survival rate of 95%. In 2007, Freed-
land et al. [2] and Hsu et al. [10] reported on 200 and 58 pa-
tient cohorts respectively with identical 5 and 10 year PCa 
specific survival of 98% and 91%. More recently in 2009, Xyli-
nas et al. [11,12] published a similar series of 100 patients with 
a 90% 5 year disease specific survival rate. These survival rates 
favor comparatively to published rates for other treatment 
modalities, namely radiotherapy with and without androgen 
deprivation. Bolla et al. [13] published EORTC (European Or-
ganisation for Research and Treatment of Cancer) long term 
results in 2002 of patients who underwent immediate andro-
gen deprivation and primary external beam radiotherapy. Of 
their 412 patients with a median follow up of 66 months, the 
reported 5 year cancer specific survival rates were 40% and 
74% for patients receiving radiotherapy alone and combined 
treatment respectively [13]. 
 A study published in Cancer comparing outcomes of 
surgery and radiotherapy with and without androgen de-
privation further validates the role of surgery as a treatment 
option for locally advanced disease. Boorjian et al. [14] retro-
spectively examined 2 large databases of patients with high-
risk PCa treated with either radiation therapy or RRP. In total, 
1,238 patients underwent RRP, and 609 patients received 
with external beam radiotherapy (EBRT; 344 received EBRT 
plus androgen deprivation therapy [ADT], and 265 received 
EBRT alone), between 1988 and 2004. The median follow-
up was 10.2 years, 6.0 years, and 7.2 years after RRP, EBRT 
plus ADT, and EBRT alone, respectively. The 10-year cancer-
specific survival rate was 92%, 92%, and 88% after RRP, EBRT 
plus ADT, and EBRT alone, respectively (P=0.06). The risk 
of all-cause mortality, however, was greater after EBRT plus 
ADT than after RRP (HR, 1.60; 95% CI, 1.25 to 2.05; P=0.0002) 
[14,15]. 
 Over the last five years, robotic surgery has become in-
creasingly utilized for the treatment of PCa, however, primar-
ily for those patients with localized disease. Although long 
term oncologic data for RALP is not yet available, excellent 
visualization, enhanced instrument familiarity and surgical 
precision has lead to the popularity of the robotic approach. 
Additionally, aggressive marketing and the advantages of 
minimally invasive surgery, including shorter hospital stay, 
less postoperative pain and blood loss has led to an increase 
in the demand of this modality for primary treatment. The 
goal of this study was to evaluate whether robotic surgery can 
be safely offered to those patients with locally advanced dis-
eases by closely examining oncologic outcomes. 
 In 2009, Ham et al. [3] published a series of 121 patients 
with locally advanced PCa evaluating the feasibility of robotic 
surgery for primary treatment. In their study, 48.8% of patients 
had positive margins on final pathology. Jayram et al. [16] 
more recently reported oncologic outcomes for a group of 
high risk PCa patients (PSA≥20 ng/mL, clinical stage≥T2c, 
or preoperative Gleason grade≥8) who underwent robotic 
assisted prostatectomy. The total rate of positive surgical mar-
gins was 20.9% and final pathology demonstrated extracap-
sular disease in 54.1% of their patients. At 2 years of follow-up, 
21.3% of patients had experienced biochemical recurrence or 
had persistent disease after treatment [16].
 In our experience, results were similar with 47.1% of patients 
exhibiting positive margins on final pathology. With a mean 
follow up 4.5 years, 18.5% of the RALP had biochemical re-
currence. When compared to our historical cohort who un-
derwent RRP for T3 disease, there was trend towards a lower 
positive margin rate (58.9% vs. 47.1%), however, this did not 
meet statistical significance (P=0.08). Additionally, there 
were no significant differences in the rate of biochemical re-
currence (18.9% vs. 18.5%, P=0.94) between the two cohorts. 
Median biochemical free recurrence was 12 months for both 
groups and there were no statistically significant differences 
on logistic regression or Kaplan-Meier analyses.
 Furthermore, we have found that with increasing surgical 
experience, oncologic outcomes improved. When comparing 
our latter 700 RALP cases with our first 300, the positive mar-
gin rate was significantly lower after a higher volume of cases 
(66.7% vs. 39.4%, P=0.004). Kaplan-Meier analysis of the 
cohorts shows a significant biochemical recurrence-free sur-
vival advantage of our latter cases at 24 months of follow-up 
(Fig. 1). Median length of biochemical recurrence-free sur-
vival was three months in our initial cohort with an increase 
to 24 months with more experience (95% CI, 0.19 to 1.13; HR, 
0.46; P=0.009) (Table 2). 
 This data mimics several other studies that have shown that 
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after the learning curve for robotic surgery has been reached, 
surgical outcomes improve. Notably, a study from Tulane 
University in 2006 evaluated positive surgical margin rates 
with increasing surgical experience for those undergoing 
RALP. Atug et al. [17] found that after 100 consecutive cases, 
the positive margin rate of their last third was significantly 
better than the first third, concluding that oncologic outcome 
is affected by the experience of the robotic surgeon. Addi-
tional studies from high volume robotic surgery centers also 
share the same experience as the authors experienced greater 
oncologic outcomes with more experience [18-20].
 While the existing data on robotically treated locally ad-
vanced PCa remains limited, we present the first comparison 
to our knowledge of oncologic outcomes for those undergo-
ing open and robotic prostatectomy for pT3 disease. Our 
results have shown that robotic surgical treatment gives com-
parable oncologic outcomes to open surgery. This study is 
not without its limitations. It’s retrospective nature, no central 
pathologic review, and variable follow-up among patients 
may produce bias in our results. Additionally, pathologic 
nodal status was not able to be obtained on all our patients 
and was left out of our review. Despite this, there appears to 
be an emerging role for robotic prostatectomy in patients 
with locally advanced disease, however, additional studies 
are needed to validate the results shown from our experience.
 In conclusion, up to 2 out of 3 men undergoing RALP for 
locally-advanced PCa had positive margins during our initial 
experience. With increasing surgeon experience, the overall 
positive margin rate decreased significantly and was com-
parable to that of patients undergoing RRP for advanced dis-
ease at our institution. With short-term follow-up, there is a 
comparable rate of biochemical recurrence between the two 
groups. Given this data, we conclude that RALP and RRP have 
comparable oncologic outcomes in advanced PCa, especially 
with higher volume surgeons.
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